Targeting of CDK9 with indirubin 3’-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice

Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID “Meet the Experts” 2015 Workshop Summary

(2016) Ramesh Akkina et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Targeting CDK9: a promising therapeutic opportunity in prostate cancer

(2016) Muhammed H Rahaman et al.   ENDOCRINE-RELATED CANCER

Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)

(2015) Kami Maddocks et al.   AMERICAN JOURNAL OF HEMATOLOGY

Oral Administration of the Nucleoside EFdA (4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine) Provides Rapid Suppression of HIV Viremia in Humanized Mice and Favorable Pharmacokinetic Properties in Mice and the Rhesus Macaque

(2015) Cheryl A. Stoddart et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Selective inhibition of HIV-1 replication by the CDK9 inhibitor FIT-039

(2015) Mika Okamoto et al.   ANTIVIRAL RESEARCH

Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia

(2015) Mark C. Lanasa et al.   LEUKEMIA RESEARCH

Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice

(2015) Alonso Heredia et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency

(2015) Guillaume Mousseau et al.   mBio

Indirubin 3′-Monoxime, from a Chinese Traditional Herbal Formula, Suppresses Viremia in Humanized Mice Infected with Multidrug-Resistant HIV

(2014) Alonso Heredia et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice

(2014) Ariel Halper-Stromberg et al.   CELL

Generation of improved humanized mouse models for human infectious diseases

(2014) Michael A. Brehm et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1

(2013) Alonso Heredia et al.   AIDS

Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma

(2013) Jeffrey A. Jones et al.   AMERICAN JOURNAL OF HEMATOLOGY

A phase I trial of flavopiridol in relapsed multiple myeloma

(2013) Craig C. Hofmeister et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

(2013) Ivana Gojo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer

(2013) Monica M. Mita et al.   Clinical Breast Cancer

Humanized mice for the study of infectious diseases

(2013) Michael A Brehm et al.   CURRENT OPINION IN IMMUNOLOGY

Targeting of the Purine Biosynthesis Host Cell Pathway Enhances the Activity of Tenofovir Against Sensitive and Drug-Resistant HIV-1

(2013) A. Heredia et al.   JOURNAL OF INFECTIOUS DISEASES

Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer

(2013) Joe J. Stephenson et al.   LUNG CANCER

Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target

(2012) Vladimir Krystof et al.   CURRENT PHARMACEUTICAL DESIGN

A Phase 2 Trial of Flavopiridol (Alvocidib) and Cisplatin in Platin-Resistant Ovarian and Primary Peritoneal Carcinoma: MC0261

(2012) Keith C. Bible et al.   GYNECOLOGIC ONCOLOGY

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

(2012) J. E. Karp et al.   HAEMATOLOGICA

Effect of Mimetic CDK9 Inhibitors on HIV-1-Activated Transcription

(2012) Rachel Van Duyne et al.   JOURNAL OF MOLECULAR BIOLOGY

Humanized Mice Recapitulate Key Features of HIV-1 Infection: A Novel Concept Using Long-Acting Anti-Retroviral Drugs for Treating HIV-1

(2012) Marc Nischang et al.   PLoS One

Activation of P-TEFb at Sites of Dual HIV/TB Infection, and Inhibition of MTB-Induced HIV Transcriptional Activation by the Inhibitor of CDK9, Indirubin-3′-Monoxime

(2011) Zahra Toossi et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Indirubin-3'-monoxime rescues spatial memory deficits and attenuates β-amyloid-associated neuropathology in a mouse model of Alzheimer's disease

(2010) Yun Ding et al.   NEUROBIOLOGY OF DISEASE

Neurologic disease burden in treated HIV/AIDS predicts survival: A population-based study

(2010) P. Vivithanaporn et al.   NEUROLOGY

Inhibition of human immunodeficiency virus type-1 by cdk inhibitors

(2010) Irene Guendel et al.   AIDS Research and Therapy

The transport of anti-HIV drugs across blood–CNS interfaces: Summary of current knowledge and recommendations for further research

(2009) Lavanya Varatharajan et al.   ANTIVIRAL RESEARCH

Suppression of Human Immunodeficiency Virus Type 1 (HIV-1) Viremia with Reverse Transcriptase and Integrase Inhibitors, CD4+ T-Cell Recovery, and Viral Rebound upon Interruption of Therapy in a New Model for HIV Treatment in the Humanized Rag2-/- c-/- Mouse

(2009) S. K. Choudhary et al.   JOURNAL OF VIROLOGY

T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice

(2008) Priti Kumar et al.   CELL